Loading...
•
Jun 30, 2025
IDEXX Q2 2025 Earnings Report
IDEXX reported strong second quarter performance with double-digit revenue growth and record EPS.
Key Takeaways
IDEXX delivered robust financial results in Q2 2025, driven by strong growth in Companion Animal Group diagnostics and record instrument placements. EPS rose 49% as reported, while international growth outpaced domestic gains.
Revenue reached $1.11 billion, up 11% year-over-year
EPS increased 49% to $3.63, including discrete tax benefits
Net income rose to $293.99 million for the quarter
Record placements of IDEXX inVue Dxâ„¢ instruments fueled capital revenue growth
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
IDEXX raised full-year 2025 guidance across revenue, EPS, and operating margin due to strong Q2 results and favorable foreign exchange impacts.
Positive Outlook
- Raised FY25 revenue guidance to $4.205B–$4.28B
- Improved organic growth outlook to 7%–9%
- EPS guidance increased to $12.40–$12.76
- Operating margin projected at 31.3%–31.6%
- Foreign exchange expected to add $0.12 to EPS
Challenges Ahead
- Rapid assay product revenues declined 3% YoY
- LPD segment income showed a loss of $505,000
- Cash and cash equivalents down from $288M to $165M QoQ
- Operating cash flow decreased YoY in Q2
- Gross margin gains partially offset by inflationary impacts
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...